221 related articles for article (PubMed ID: 27617608)
1. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi T; Martin S; Worswick S
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
McCormack PL
Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
10. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y
Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582
[TBL] [Abstract][Full Text] [Related]
11. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
12. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
14. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
15. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
Gunes H; Kivrak T
Curr Drug Saf; 2016; 11(2):174-6. PubMed ID: 26560493
[TBL] [Abstract][Full Text] [Related]
17. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
[No Abstract] [Full Text] [Related]
18. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial.
Bowen CJ; Lobb KM; Park JW; Sanderson B; Ferguson J
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):243-9. PubMed ID: 20831698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]